Translation Transcription Infidelity (TI)
Into Multiple Affordable Cures
For Both Human and Animals
Slider

GENOMIC
CLINICAL
SYNERGY

Genclis SA is a biotechnology company focused on developing therapies for both human and animal health using Transcription Infidelity (“TI”). TI is a patented process that begins by analyzing differences between RNA and DNA sequences to identify translated proteins capable of causing the production of either Immunoglobulin E (“IgE”), the antibody responsible for most forms of allergies or Immunoglobulin G (“IgG”), the workhorse of immunity that accounts for most of vaccine efficacy. Genclis uses its proprietary patented platform technology to develop therapies that elicit self-produced antibodies that block disease-causing proteins irrespective of their endogenous or exogenous origin.

 

 

dna 1903318

Science of TI

Transcription infidelity An Ubiquitous Biological process

Read more about Science of TI

 


To develop tools required for precise medicine

 



« The difference between a low-intensity signal that precedes any major transformation and noise is that the second is random, while the first is not. »

Bernard Bihain, CEO

Newsroom